📰 Nuclear Export News
Page 5 - Nuclear Export News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nuclear Export. Real-time updates on events, politics, business and more.
September 1, 2023
NEWTON, Mass., Sept. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an...
September 1, 2023
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
August 20, 2023
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has earned an average rating of “Moderate Buy” from the five analysts that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among analysts […]
August 5, 2023
Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They presently have a $10.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 481.40% from the stock’s previous close. Several […]
August 2, 2023
– Achieved Second Quarter 2023 Total Revenue of $37.6 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.5 Million – – Maintains Full Year 2023...
July 30, 2023
HC Wainwright reiterated their buy rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI – Free Report) in a report issued on Wednesday morning, Benzinga reports. They currently have a $10.00 price target on the stock. A number of other analysts have also weighed in on KPTI. Robert W. Baird reduced their price target on shares of […]
July 26, 2023
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it...
July 25, 2023
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the...
July 20, 2023
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) saw a significant decline in short interest in the month of June. As of June 30th, there was short interest totalling 12,550,000 shares, a decline of 24.0% from the June 15th total of 16,520,000 shares. Based on an average daily trading volume, of 2,890,000 shares, the days-to-cover […]
July 20, 2023
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) saw a large drop in short interest in the month of June. As of June 30th, there was short interest totalling 12,550,000 shares, a drop of 24.0% from the June 15th total of 16,520,000 shares. Based on an average trading volume of 2,890,000 shares, the days-to-cover ratio […]